Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative FOLFIRINOX for Localized Pancreatic Cancer
NCT03167112Phase 2Unknown
- Start
- Jul 2017
- Primary completion
- Mar 2018
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of oxaliplatin, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, folinic acid, fluorouracil in Pancreatic ductal adenocarcinoma (PDAC). Status: unknown.
02
Drugs
oxaliplatinirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabfolinic acidfluorouracil
03
Conditions
Pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03167112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03167112.